ArticleFrontiers in oncology2022
The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Knowledge mapping of global trends in DNA damage repair-related breast cancer research: a bibliometric study.Frontiers in oncology · 2025Pooled it
- A bibliometric study on the impact of gut microbiota on the efficacy of immune checkpoint inhibitors in cancer patients: analysis of the top 100 cited articles.Frontiers in immunology · 2024Pooled it
- Association between gut microbiota and hepatocellular carcinoma from 2011 to 2022: Bibliometric analysis and global trends.Frontiers in oncology · 2023Pooled it
- From diversity to function: microbiome precision in RCC.Nature reviews. Urology · 2026Article
- Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy.Molecular oncology · 2026Article
- Microbiome and pancreatic ductal adenocarcinoma: mechanistic insights, microenvironmental interactions, and therapeutic implications.Molecular biology reports · 2026Review
- Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung Cancer.Research square · 2026Article
- Gut Microbiome Composition and Response to Immune Checkpoint Inhibitors in Melanoma: A Systematic Review.Cureus · 2026Review
- Targeting the microbiota-miRNA-protease axis: A new therapeutic avenue in melanoma.The FEBS journal · 2026Review
- Gut microbiota diversity in patients with ESCC: associations with esophagectomy, the tumor immune microenvironment, and nivolumab response.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Review
- Across the Social Network of the Gut: Bacterial, Fungal, and Viral Determinants of Checkpoint Inhibitor Efficacy and Toxicity.International journal of molecular sciences · 2026Review
- Microbiome as a prediction of immunotherapy response in lung cancer.Frontiers in immunology · 2026Review
- Impact of immune-related adverse events on treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors.Frontiers in immunology · 2026Article
- Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy.Oncology research · 2026Review
- Mechanism of anticancer action ofOncotarget · 2025Review
- Gut Microbiome Alterations in Colorectal Cancer: Mechanisms, Therapeutic Strategies, and Precision Oncology Perspectives.Cancers · 2025Review
- Gut microbiome associated with PARP inhibitor efficacy in patients with ovarian cancer.Journal of gynecologic oncology · 2025Article
- Causal effect of gut microbiota on the risk of cancer and potential mediation by inflammatory proteins.World journal of surgical oncology · 2025Article
- Unveiling the interplay between microbiota and PD1/PD-L1 axis in tumor immunity and immunotherapy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) have been widely used in treating different malignancies. Several studies have reported that the gut microbiota modulates the response and adverse events (AEs) to ICIs in melanoma, non-small cell lung cancer (NSCLC), renal cell cancer and hepatocellular carcinoma, but data on other cancer types and ICI combination therapy are limited. Methods: Stool samples were collected from patients with cancer who received anti-PD-1 and chemotherapy combination treatment and were analyzed by fecal metagenomic sequencing. The microbiota diversity and composition were compared between the responder (R) and non-responder (NR) groups and the AE vs. the non-AE (NAE) groups. In addition, associated functional genes and metabolic pathways were identified. Results: At baseline, the microbiota diversity of the groups was similar, but the genera Conclusion: Beta diversity and differences in the gut microbiota modulated AEs and the response to anti-PD-1 blockade combined with chemotherapy, by regulating related anabolic and DDR pathways. Dynamic changes in the intestinal microbiome may predict the efficacy of PD-1 inhibitor-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.